1. Clinical Application of Cytokines in Cancer Immunotherapy
    Yi Qiu et al, 2021, Drug Design, Development and Therapy CrossRef
  2. Molecular mechanisms of the anti-cancer drug, LY2874455, in overcoming the FGFR4 mutation-based resistance
    Fariba Dehghanian et al, 2021, Scientific Reports CrossRef
  3. A new screening tool for FGFR inhibitor treatment?
    Aung Naing, 2019, The Lancet Oncology CrossRef
  4. Combined CDK4/6 and PD-1 Inhibition in Refractory SMARCA4-Deficient Small-Cell Carcinoma of the Ovary, Hypercalcemic Type
    Elizabeth K. Lee et al, 2020, JCO Precision Oncology CrossRef
  5. Fibroblast growth factor receptor 1 and 3 expression is associated with regulatory PI3K/AKT kinase activity, as well as invasion and prognosis, in human laryngeal cancer
    Katarzyna Starska et al, 2018, Cellular Oncology CrossRef
  6. Gene expression profiling in aggressive digital papillary adenocarcinoma sheds light on the architecture of a rare sweat gland carcinoma
    H.M. Surowy et al, 2019, British Journal of Dermatology CrossRef
  7. Structure, activation and dysregulation of fibroblast growth factor receptor kinases: perspectives for clinical targeting
    Brendan Farrell et al, 2018, Biochemical Society Transactions CrossRef
  8. Deciphering the whale's secrets to have a long life
    Francisco Alejandro Lagunas-Rangel, 2021, Experimental Gerontology CrossRef
  9. Design, synthesis and biological evaluation of a series of novel 2-benzamide-4-(6-oxy-N-methyl-1-naphthamide)-pyridine derivatives as potent fibroblast growth factor receptor (FGFR) inhibitors
    Manman Wei et al, 2018, European Journal of Medicinal Chemistry CrossRef
  10. Critical role of the fibroblast growth factor signalling pathway in Ewing's sarcoma octamer‐binding transcription factor 4‐mediated cell proliferation and tumorigenesis
    Junghoon Kim et al, 2019, The FEBS Journal CrossRef
  11. Optimization of 1H-indazol-3-amine derivatives as potent fibroblast growth factor receptor inhibitors
    Jing Cui et al, 2017, Bioorganic & Medicinal Chemistry Letters CrossRef
  12. Targeted Therapy for Advanced or Metastatic Cholangiocarcinoma: Focus on the Clinical Potential of Infigratinib
    James Yu et al, 2021, OncoTargets and Therapy CrossRef
  13. Dual target inhibitors based on EGFR: Promising anticancer agents for the treatment of cancers (2017-)
    Liping Hu et al, 2022, European Journal of Medicinal Chemistry CrossRef
  14. The diagnostic and clinicopathological value of trefoil factor 3 in patients with gastric cancer: a systematic review and meta-analysis
    Chen-Xing Zhang et al, 2021, Biomarkers CrossRef
  15. The protein-protein interaction network of intestinal gastric cancer patients reveals hub proteins with potential prognostic value
    Everton Cruz Santos et al, 2021, Cancer Biomarkers CrossRef
  16. Safflower Polysaccharide Inhibits AOM/DSS-Induced Mice Colorectal Cancer Through the Regulation of Macrophage Polarization
    Qun Wang et al, 2021, Frontiers in Pharmacology CrossRef
  17. Fibroblast growth factor receptor inhibitors: patent review (2015–2019)
    Giuseppe Marseglia et al, 2019, Expert Opinion on Therapeutic Patents CrossRef
  18. Chicken-Derived Humanized Antibody Targeting a Novel Epitope F2pep of Fibroblast Growth Factor Receptor 2: Potential Cancer Therapeutic Agent
    Keng-Chang Tsai et al, 2019, ACS Omega CrossRef
  19. Fibroblast Growth Factor Receptor Signaling in Skin Cancers
    Malgorzata Czyz, 2019, Cells CrossRef
  20. Development of an Immune-Related Risk Signature for Predicting Prognosis in Lung Squamous Cell Carcinoma
    Denggang Fu et al, 2020, Frontiers in Genetics CrossRef
  21. MiR‐16‐1‐3p and miR‐16‐2‐3p possess strong tumor suppressive and antimetastatic properties in osteosarcoma
    Vadim V. Maximov et al, 2019, International Journal of Cancer CrossRef
  22. Quantification of FGFR4 inhibitor BLU-554 in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry
    Burcu Dogan-Topal et al, 2019, Journal of Chromatography B CrossRef
  23. The future of bladder cancer therapy: Optimizing the inhibition of the fibroblast growth factor receptor
    Rafael Morales-Barrera et al, 2020, Cancer Treatment Reviews CrossRef
  24. Heart failure as interstitial cancer: emergence of a malignant fibroblast phenotype
    Kelsie E. Oatmen et al, 2020, Nature Reviews Cardiology CrossRef
  25. Oncogenic FGFR Fusions Produce Centrosome and Cilia Defects by Ectopic Signaling
    Alexandru Nita et al, 2021, Cells CrossRef
  26. The Upregulation of PLXDC2 Correlates with Immune Microenvironment Characteristics and Predicts Prognosis in Gastric Cancer
    Yang Li et al, 2021, Disease Markers CrossRef
  27. A functional outside-in signaling network of proteoglycans and matrix molecules regulating autophagy
    Thomas Neill et al, 2021, Matrix Biology CrossRef
  28. FGFR Inhibitors: Clinical Activity and Development in the Treatment of Cholangiocarcinoma
    Gentry King et al, 2021, Current Oncology Reports CrossRef
  29. Cancer-related FGFR2 overexpression and gene amplification in Japanese patients with gastric cancer
    Keiko Minashi et al, 2021, Japanese Journal of Clinical Oncology CrossRef
  30. The Combined Effect of FGFR Inhibition and PD-1 Blockade Promotes Tumor-Intrinsic Induction of Antitumor Immunity
    Sangeetha Palakurthi et al, 2019, Cancer Immunology Research CrossRef
  31. Identifying Lung Cancer Cell Markers with Machine Learning Methods and Single-Cell RNA-Seq Data
    Guo-Hua Huang et al, 2021, Life CrossRef
  32. Selective FGFR inhibitor BGJ398 inhibits phosphorylation of AKT and STAT3 and induces cytotoxicity in sphere-cultured ovarian cancer cells
    Hwa Jun Cha et al, 2017, International Journal of Oncology CrossRef
  33. FGFR4 Arg388 Is Correlated with Poor Survival in Resected Colon Cancer Promoting Epithelial to Mesenchymal Transition
    Sang Hee Cho et al, 2017, Cancer Research and Treatment CrossRef
  34. Non-mitogenic FGF2 protects cardiomyocytes from acute doxorubicin-induced toxicity independently of the protein kinase CK2/heme oxygenase-1 pathway
    Navid Koleini et al, 2018, Cell and Tissue Research CrossRef
  35. Functions of FGFR2 corrupted by translocations in intrahepatic cholangiocarcinoma
    Fangda Li et al, 2020, Cytokine & Growth Factor Reviews CrossRef
  36. A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours
    K P Papadopoulos et al, 2017, British Journal of Cancer CrossRef
  37. Novel Regulatory Factors and Small-Molecule Inhibitors of FGFR4 in Cancer
    Yanan Liu et al, 2021, Frontiers in Pharmacology CrossRef
  38. Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance
    Melanie A. Krook et al, 2021, British Journal of Cancer CrossRef
  39. Molecular defects in BRAF wild-type ameloblastomas and craniopharyngiomas—differences in mutation profiles in epithelial-derived oropharyngeal neoplasms
    Stephan Bartels et al, 2018, Virchows Archiv CrossRef
  40. Klotho negatively regulated aerobic glycolysis in colorectal cancer via ERK/HIF1α axis
    Qingguo Li et al, 2018, Cell Communication and Signaling CrossRef
  41. Importance of Translational Research for Targeting Fibroblast Growth Factor Receptor Signaling in Cancer
    null Holzmann et al, 2019, Cells CrossRef
  42. New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma
    Sara Massironi et al, 2020, Cells CrossRef
  43. Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase III REFLECT Study
    Richard S. Finn et al, 2021, Clinical Cancer Research CrossRef
  44. Assessment of FGFR1 Over-Expression and Over-Activity in Lung Cancer Cells: A Toolkit for Anti-FGFR1 Drug Screening
    Penghui Hu et al, 2018, Human Gene Therapy Methods CrossRef
  45. Growth Factors in the Intestinal Tract
    Michael A. Schumacher et al, 2018, Physiology of the Gastrointestinal Tract CrossRef
  46. Genomic testing, tumor microenvironment and targeted therapy of Hedgehog-related human cancers
    Masaru Katoh, 2019, Clinical Science CrossRef
  47. Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)
    R. Condorelli et al, 2019, Annals of Oncology CrossRef
  48. MiR-497 promotes microglia activation and proinflammatory cytokines production in chronic unpredictable stress-induced depression via targeting FGF2
    Xiaoyan Zhai et al, 2020, Journal of Chemical Neuroanatomy CrossRef
  49. Intrahepatic Cholangiocarcinoma: State of the Art of FGFR Inhibitors
    Tianyu Wu et al, 2021, Cancer Control CrossRef
  50. Rab8 and Rabin8-Mediated Tumor Formation by Hyperactivated EGFR Signaling via FGFR Signaling
    Junghwa Choi et al, 2020, International Journal of Molecular Sciences CrossRef
  51. Cancer immunotherapy: Pros, cons and beyond
    Shuzhen Tan et al, 2020, Biomedicine & Pharmacotherapy CrossRef
  52. Inferring Novel Tumor Suppressor Genes with a Protein-Protein Interaction Network and Network Diffusion Algorithms
    Lei Chen et al, 2018, Molecular Therapy - Methods & Clinical Development CrossRef
  53. Targeted therapies for advanced bladder cancer: new strategies with FGFR inhibitors
    Chiara Casadei et al, 2019, Therapeutic Advances in Medical Oncology CrossRef
  54. Fibroblast growth factor receptor fusions in cancer: opportunities and challenges
    Lingfeng Chen et al, 2021, Journal of Experimental & Clinical Cancer Research CrossRef
  55. Melatonin Suppresses Oral Squamous Cell Carcinomas Migration and Invasion through Blocking FGF19/FGFR 4 Signaling Pathway
    Leilei Wang et al, 2021, International Journal of Molecular Sciences CrossRef
  56. Effects of FGFR inhibitors TKI258, BGJ398 and AZD4547 on breast cancer cells in 2D, 3D and tissue explant cultures
    T. E. Kähkönen et al, 2021, Cellular Oncology CrossRef
  57. Involvement of FGFR4 Gene Variants on the Clinicopathological Severity in Urothelial Cell Carcinoma
    Ming-Dow Tsay et al, 2019, International Journal of Environmental Research and Public Health CrossRef
  58. Therapeutics Targeting FGF Signaling Network in Human Diseases
    Masaru Katoh, 2016, Trends in Pharmacological Sciences CrossRef
  59. Expression of 17β-hydroxysteroid dehydrogenase type 1 in gastric cancer
    Bartosz Adam Frycz et al, 2013, Biomedicine & Pharmacotherapy CrossRef
  60. Fibroblast Growth Factor Receptors (FGFRs): Structures and Small Molecule Inhibitors
    Shuyan Dai et al, 2019, Cells CrossRef
  61. Soluble interleukin-2 receptor as a factor associated with angiogenesis in gastric cancer
    Wen-Feng Yan et al, 2017, Molecular Medicine Reports CrossRef
  62. Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy
    Charles Pottier et al, 2020, Cancers CrossRef
  63. Inhibition of FGF‐FGFR and VEGF‐VEGFR signalling in cancer treatment
    Guihong Liu et al, 2021, Cell Proliferation CrossRef
  64. FGFR2-Driven Signaling Counteracts Tamoxifen Effect on ERα-Positive Breast Cancer Cells
    Lukasz Turczyk et al, 2017, Neoplasia CrossRef
  65. Recent developments and advances of FGFR as a potential target in cancer
    Wen-Jun Xue et al, 2018, Future Medicinal Chemistry CrossRef
  66. Novel targetable FGFR2 and FGFR3 alterations in glioblastoma associate with aggressive phenotype and distinct gene expression programs
    Maria-Magdalena Georgescu et al, 2021, Acta Neuropathologica Communications CrossRef
  67. Fibroblasts as immune regulators in infection, inflammation and cancer
    Sarah Davidson et al, 2021, Nature Reviews Immunology CrossRef
  68. Genetics of breast cancer bone metastasis: a sequential multistep pattern
    Hassan Fazilaty et al, 2014, Clinical & Experimental Metastasis CrossRef
  69. Perforation of the Small Intestine after Introduction of Lenvatinib in a Patient with Advanced Hepatocellular Carcinoma
    Naomi Suzuki et al, 2020, Case Reports in Gastroenterology CrossRef
  70. Glioma cell-derived FGF20 suppresses macrophage function by activating β-catenin
    Xue Cai et al, 2022, Cellular Signalling CrossRef
  71. Comprehensive functional evaluation of variants of fibroblast growth factor receptor genes in cancer
    Ikuko Takeda Nakamura et al, 2021, npj Precision Oncology CrossRef
  72. Myeloid/lymphoid neoplasms withFGFR1rearrangement
    Paolo Strati et al, 2018, Leukemia & Lymphoma CrossRef
  73. Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study
    Martin Schuler et al, 2019, The Lancet Oncology CrossRef
  74. Development and Characterization of a Novel Peptide—Drug Conjugate with DM1 for Treatment of FGFR2-Positive Tumors
    Yayu Wang et al, 2021, Biomedicines CrossRef
  75. Precise editing of FGFR3-TACC3 fusion genes with CRISPR-Cas13a in glioblastoma
    Ye Wu et al, 2021, Molecular Therapy CrossRef
  76. Genetics of Pheochromocytomas and Paragangliomas
    Rodrigo Almeida Toledo, 2017, Endocrinology and Metabolism Clinics of North America CrossRef
  77. Canonical and non-canonical WNT signaling in cancer stem cells and their niches: Cellular heterogeneity, omics reprogramming, targeted therapy and tumor plasticity (Review)
    Masaru Katoh, 2017, International Journal of Oncology CrossRef
  78. Silencing fibroblast growth factor 7 inhibits krypton laser‐induced choroidal neovascularization in a rat model
    Chao Zhang et al, 2019, Journal of Cellular Biochemistry CrossRef
  79. Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study
    Jianming Xu et al, 2020, The Lancet Oncology CrossRef
  80. Blockade of Fgfr1 with PD166866 Protects Cartilage from the Catabolic Effects Induced by Interleukin-1β: A Genome-Wide Expression Profiles Analysis
    Lingxian Yi et al, 2020, CARTILAGE CrossRef
  81. The transformics assay: first steps for the development of an integrated approach to investigate the malignant cell transformation in vitro
    Maria Grazia Mascolo et al, 2018, Carcinogenesis CrossRef
  82. Recent advances of dual FGFR inhibitors as a novel therapy for cancer
    Qi Liang et al, 2021, European Journal of Medicinal Chemistry CrossRef
  83. Surufatinib: First Approval
    Yahiya Y. Syed, 2021, Drugs CrossRef
  84. FGFR Inhibitors in Oncology: Insight on the Management of Toxicities in Clinical Practice
    Anuhya Kommalapati et al, 2021, Cancers CrossRef
  85. Comprehending fibroblast growth factor receptor like 1: Oncogene or tumor suppressor?
    null Aprajita et al, 2021, Cancer Treatment and Research Communications CrossRef
  86. Fibroblast Growth Factor 9 is expressed by activated hepatic stellate cells and promotes progression of hepatocellular carcinoma
    Tatjana Seitz et al, 2020, Scientific Reports CrossRef
  87. Dermatologic Adverse Events Associated with Selective Fibroblast Growth Factor Receptor Inhibitors: Overview, Prevention, and Management Guidelines
    Mario E. Lacouture et al, 2021, The Oncologist CrossRef
  88. Fibroblast growth factor receptors as treatment targets in clinical oncology
    Masaru Katoh, 2019, Nature Reviews Clinical Oncology CrossRef
  89. Tumor microenvironment – Unknown niche with powerful therapeutic potential
    Tomasz Kolenda et al, 2018, Reports of Practical Oncology & Radiotherapy CrossRef
  90. Splice variants of porcine PPHLN1 encoding periphilin-1
    Knud Larsen et al, 2017, Gene Reports CrossRef
  91. The Evolving Role of Companion Diagnostics for Breast Cancer in an Era of Next-Generation Omics
    Jason N. Rosenbaum et al, 2017, The American Journal of Pathology CrossRef
  92. The integration of genomics testing and functional proteomics in the era of personalized medicine
    Masaru Katoh, 2017, Expert Review of Proteomics CrossRef
  93. Involvement of mitogen activated kinase kinase 7 intracellular signalling pathway in Sunitinib-induced cardiotoxicity
    Samantha Louise Cooper et al, 2018, Toxicology CrossRef
  94. Discovery and optimization of novel pyrazole-benzimidazole CPL304110, as a potent and selective inhibitor of fibroblast growth factor receptors FGFR (1–3)
    Abdellah Yamani et al, 2021, European Journal of Medicinal Chemistry CrossRef
  95. Activated ERK Signaling Is One of the Major Hub Signals Related to the Acquisition of Radiotherapy-Resistant MDA-MB-231 Breast Cancer Cells
    Anjugam Paramanantham et al, 2021, International Journal of Molecular Sciences CrossRef
  96. Novel pyrrole derivatives bearing sulfonamide groups: Synthesis in vitro cytotoxicity evaluation, molecular docking and DFT study
    Masoumeh Bavadi et al, 2017, Journal of Molecular Structure CrossRef
  97. FGF10/FGF17 as prognostic and drug response markers in acute myeloid leukemia
    Yanying Ling et al, 2022, Current Research in Translational Medicine CrossRef
  98. Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor
    Timothy P.S. Perera et al, 2017, Molecular Cancer Therapeutics CrossRef
  99. Aberrant expression of intelectin-1 in gastric cancer: its relationship with clinicopathological features and prognosis
    Liduan Zheng et al, 2012, Journal of Cancer Research and Clinical Oncology CrossRef
  100. bFGF in tumor tissue independently prognosticates disease outcome of a natural course of invasive breast cancer
    Nataša Todorović-Raković et al, 2017, Cancer Biomarkers CrossRef
  101. Clinical Characteristics and Spermatogenesis in Patients with Congenital Hypogonadotropic Hypogonadism Caused by FGFR1 Mutations
    Shuying Li et al, 2020, International Journal of Endocrinology CrossRef
  102. Stable Fibroblast Growth Factor 2 Dimers with High Pro-Survival and Mitogenic Potential
    Daria Nawrocka et al, 2020, International Journal of Molecular Sciences CrossRef
  103. δ-Catenin Participates in EGF/AKT/p21Waf Signaling and Induces Prostate Cancer Cell Proliferation and Invasion
    Yingjie Shen et al, 2021, International Journal of Molecular Sciences CrossRef
  104. FGFR-TKI resistance in cancer: current status and perspectives
    Sitong Yue et al, 2021, Journal of Hematology & Oncology CrossRef
  105. Stomach
    Scott A. Hundahl et al, 2006, Oncology CrossRef
  106. Dovitinib Triggers Apoptosis and Autophagic Cell Death by Targeting SHP-1/p-STAT3 Signaling in Human Breast Cancers
    Yi-Han Chiu et al, 2019, Journal of Oncology CrossRef
  107. Hepatic gene body hypermethylation is a shared epigenetic signature of murine longevity
    Oliver Hahn et al, 2018, PLOS Genetics CrossRef
  108. Case Report: Anlotinib Reverses Nivolumab Resistance in Advanced Primary Pulmonary Lymphoepithelioma-Like Carcinoma With FGFR3 Gene Amplification
    Yanyang Liu et al, 2021, Frontiers in Oncology CrossRef
  109. GPER Mediates a Feedforward FGF2/FGFR1 Paracrine Activation Coupling CAFs to Cancer Cells Toward Breast Tumor Progression
    Maria Francesca Santolla et al, 2019, Cells CrossRef
  110. Effects of Food on the Pharmacokinetic Properties of Surufatinib: A Phase I, Single-dose, Randomized, Open-label Crossover Study in Healthy Subjects
    Hongjie Qian et al, 2020, Clinical Therapeutics CrossRef
  111. Rogaratinib: A potent and selective pan‐FGFR inhibitor with broad antitumor activity in FGFR‐overexpressing preclinical cancer models
    Sylvia Grünewald et al, 2019, International Journal of Cancer CrossRef
  112. FGF/FGFR-Dependent Molecular Mechanisms Underlying Anti-Cancer Drug Resistance
    Jakub Szymczyk et al, 2021, Cancers CrossRef
  113. A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations
    Martin H. Voss et al, 2019, Clinical Cancer Research CrossRef
  114. Impact of fibroblast growth factor receptor 1 (FGFR1) amplification on the prognosis of breast cancer patients
    Ramona Erber et al, 2020, Breast Cancer Research and Treatment CrossRef
  115. TAS‐120 Cancer Target Binding: Defining Reactivity and Revealing the First Fibroblast Growth Factor Receptor 1 (FGFR1) Irreversible Structure
    Maria Kalyukina et al, 2019, ChemMedChem CrossRef
  116. Fibroblast Growth Factor Inhibitors for Treating Locally Advanced/Metastatic Bladder Urothelial Carcinomas via Dual Targeting of Tumor-Specific Oncogenic Signaling and the Tumor Immune Microenvironment
    Hye Won Lee et al, 2021, International Journal of Molecular Sciences CrossRef
  117. Sulfatinib, a novel kinase inhibitor, in patients with advanced solid tumors: results from a phase I study
    Jian Ming Xu et al, 2017, Oncotarget CrossRef
  118. Gastric cancer management: Kinases as a target therapy
    Batoul Farran et al, 2017, Clinical and Experimental Pharmacology and Physiology CrossRef
  119. Collateral Damage Intended—Cancer-Associated Fibroblasts and Vasculature Are Potential Targets in Cancer Therapy
    Ana Cavaco et al, 2017, International Journal of Molecular Sciences CrossRef
  120. Precision medicine for human cancers with Notch signaling dysregulation (Review)
    Masuko Katoh et al, 2019, International Journal of Molecular Medicine CrossRef
  121. Circulating microRNAs in patients with hormone receptor‐positive, metastatic breast cancer treated with dovitinib
    Narayan Shivapurkar et al, 2017, Clinical and Translational Medicine CrossRef
  122. Trefoil factor family (TFF) peptides and cancer progression
    Shahin Emami et al, 2004, Peptides CrossRef
  123. Advances of Fibroblast Growth Factor/Receptor Signaling Pathway in Hepatocellular Carcinoma and its Pharmacotherapeutic Targets
    Haijun Wang et al, 2021, Frontiers in Pharmacology CrossRef
  124. The effect of everolimus and low-dose cyclophosphamide on immune cell subsets in patients with metastatic renal cell carcinoma: results from a phase I clinical trial
    null null et al, 2019, Cancer Immunology, Immunotherapy CrossRef
  125. Promoting Effect of Basic Fibroblast Growth Factor in Synovial Mesenchymal Stem Cell-Based Cartilage Regeneration
    Gensuke Okamura et al, 2020, International Journal of Molecular Sciences CrossRef
  126. Epithelial Splicing Regulatory Protein (ESPR1) Expression in an Unfavorable Prognostic Factor in Prostate Cancer Patients
    Hyung Ho Lee et al, 2020, Frontiers in Oncology CrossRef
  127. Triple Angiokinase Inhibitor Nintedanib Directly Inhibits Tumor Cell Growth and Induces Tumor Shrinkage via Blocking Oncogenic Receptor Tyrosine Kinases
    Frank Hilberg et al, 2018, Journal of Pharmacology and Experimental Therapeutics CrossRef
  128. CSF1R and HCST: Novel Candidate Biomarkers Predicting the Response to Immunotherapy in Non-Small Cell Lung Cancer
    Xiaoguang Qi et al, 2020, Technology in Cancer Research & Treatment CrossRef
  129. Tumor mutation burden in connection with immune-related survival in uterine corpus endometrial carcinoma
    Ling Zhao et al, 2021, Cancer Cell International CrossRef
  130. Effects of FGFR Tyrosine Kinase Inhibition in OLN-93 Oligodendrocytes
    Ranjithkumar Rajendran et al, 2021, Cells CrossRef
  131. Prognostic importance of FGF2 and FGFR1 expression for patients affected by ameloblastoma
    Felipe Paiva Fonseca et al, 2018, Journal of Oral Pathology & Medicine CrossRef
  132. FGFR1 amplification or overexpression and hormonal resistance in luminal breast cancer: rationale for a triple blockade of ER, CDK4/6, and FGFR1
    Silvana Mouron et al, 2021, Breast Cancer Research CrossRef
  133. Urothelial carcinoma: the development of FGFR inhibitors in combination with immune checkpoint inhibitors
    Qian Qin et al, 2020, Expert Review of Anticancer Therapy CrossRef
  134. GZD824 overcomes FGFR1‐V561F/M mutant resistance in vitro and in vivo
    Kaili Jiang et al, 2021, Cancer Medicine CrossRef
  135. Analyses of publicly available genomics resources define FGF-2-expressing bladder carcinomas as EMT-prone, proliferative tumors with low mutation rates and high expression of CTLA-4, PD-1 and PD-L1
    Elizabeth A McNiel et al, 2017, Signal Transduction and Targeted Therapy CrossRef
  136. Intrinsic fluorescence of the clinically approved multikinase inhibitor nintedanib reveals lysosomal sequestration as resistance mechanism in FGFR-driven lung cancer
    Bernhard Englinger et al, 2017, Journal of Experimental & Clinical Cancer Research CrossRef
  137. A novel monovalent FGFR1 antagonist: Preclinical safety profiles in rodents and non-human primates
    Ping Yu et al, 2020, Toxicology and Applied Pharmacology CrossRef
  138. Compounds from Natural Sources as Protein Kinase Inhibitors
    Andrea Baier et al, 2020, Biomolecules CrossRef
  139. Targeting the Fibroblast Growth Factor Receptor (FGFR) Family in Lung Cancer
    Laura Pacini et al, 2021, Cells CrossRef
  140. Structural Alterations in Human Fibroblast Growth Factor Receptors in Carcinogenesis
    D. S. Mikhaylenko et al, 2018, Biochemistry (Moscow) CrossRef
  141. Antisense Oligonucleotides Targeting Angiogenic Factors as Potential Cancer Therapeutics
    Bao T. Le et al, 2019, Molecular Therapy - Nucleic Acids CrossRef
  142. The Effects of Naringenin on miRNA-mRNA Profiles in HepaRG Cells
    Weiyang Fan et al, 2021, International Journal of Molecular Sciences CrossRef
  143. Dark and bright side of targeting fibroblast growth factor receptor 4 in the liver
    Raffaella Maria Gadaleta et al, 2021, Journal of Hepatology CrossRef
  144. Fibroblast growth factor receptor inhibition induces loss of matrix MCL1 and necrosis in cholangiocarcinoma
    Ayano Kabashima et al, 2018, Journal of Hepatology CrossRef
  145. Fibroblast Growth Factor Receptor Inhibitors and Nonuremic Calciphylaxis
    Jesse Hirner et al, 2021, JAMA Dermatology CrossRef
  146. Current Status of Fibroblast Growth Factor Receptor-Targeted Therapies in Breast Cancer
    Navid Sobhani et al, 2018, Cells CrossRef
  147. Colitis induced by Lenvatinib in a patient with advanced hepatocellular carcinoma
    Saori Miyajima et al, 2021, Clinical Journal of Gastroenterology CrossRef
  148. Safety, pharmacokinetic, and pharmacodynamics of erdafitinib, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in patients with advanced or refractory solid tumors
    Tomohiro Nishina et al, 2018, Investigational New Drugs CrossRef
  149. Sialylation of FGFR1 by ST6Gal‑I overexpression contributes to ovarian cancer cell migration and chemoresistance
    Lingling Ou et al, 2020, Molecular Medicine Reports CrossRef
  150. Identification of key classification features of early cervical squamous cell carcinoma
    Xiaoxi Wang et al, 2021, Computational Biology and Chemistry CrossRef
  151. Papillomavirus E2 protein is regulated by specific fibroblast growth factor receptors
    Marsha DeSmet et al, 2018, Virology CrossRef
  152. Reversible corneal stromal thinning, acute-onset white cataract and angle-closure glaucoma due to erdafitinib, a fibroblast growth factor receptor inhibitor: Report of three cases
    G. Bauters et al, 2021, Journal Français d'Ophtalmologie CrossRef
  153. A cyclic peptide retards the proliferation of DU145 prostate cancer cells in vitro and in vivo through inhibition of FGFR2
    Yibo Zhang et al, 2020, MedComm CrossRef
  154. Extracellular vesicles as a new hope for diagnosis and therapeutic intervention for hepatocellular carcinoma
    Natthaphong Nimitrungtawee et al, 2021, Cancer Medicine CrossRef
  155. QSAR and Structure-Based Docking Studies of Aryl Pyrido[2,3-d]pyrimidin-7(8H)-ones
    Jyoti Durgapal et al, 2018, International Journal of Quantitative Structure-Property Relationships CrossRef
  156. Targeted Therapy in Metastatic Bladder Cancer: Present Status and Future Directions
    Mathijs Scholtes et al, 2020, Applied Sciences CrossRef
  157. Targeting FGFR in bladder cancer: ready for clinical practice?
    Stijn De Keukeleire et al, 2020, Acta Clinica Belgica CrossRef
  158. The Fibroblast Growth Factor Receptors in Breast Cancer: from Oncogenesis to Better Treatments
    Navid Sobhani et al, 2020, International Journal of Molecular Sciences CrossRef
  159. Deregulation of kinase signaling and lymphoid development in EBF1-PDGFRB ALL leukemogenesis
    S J Welsh et al, 2018, Leukemia CrossRef
  160. A Phase 1 Study of LY2874455, an Oral Selective pan-FGFR Inhibitor, in Patients with Advanced Cancer
    Michael Michael et al, 2017, Targeted Oncology CrossRef
  161. Targeted and novel therapy in advanced gastric cancer
    Julie H. Selim et al, 2019, Experimental Hematology & Oncology CrossRef
  162. A novel prognostic risk score model based on immune-related genes in patients with stage IV colorectal cancer
    Ke Xu et al, 2020, Bioscience Reports CrossRef
  163. Discovery and optimization of selective FGFR4 inhibitors via scaffold hopping
    Yikai Wang et al, 2017, Bioorganic & Medicinal Chemistry Letters CrossRef
  164. Computational Simulation Studies on the Binding Selectivity of 1-(1H-Benzimidazol-5-yl)-5-aminopyrazoles in Complexes with FGFR1 and FGFR4
    You-Lu Pan et al, 2018, Molecules CrossRef
  165. Future applications of FGF/FGFR inhibitors in cancer
    Gaia Cristina Ghedini et al, 2018, Expert Review of Anticancer Therapy CrossRef
  166. MicroRNA-198 inhibits proliferation and induces apoptosis by directly suppressing FGFR1 in gastric cancer
    Junxia Gu et al, 2019, Bioscience Reports CrossRef
  167. Extracellular vesicles from senescent hepatic stellate cells promote cell viability of hepatoma cells through increasing EGF secretion from differentiated THP‑1 cells
    Yuri Miyazoe et al, 2020, Biomedical Reports CrossRef
  168. Making way for suppressing the FGF19/FGFR4 axis in cancer
    Nestor Prieto-Dominguez et al, 2018, Future Medicinal Chemistry CrossRef
  169. The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder
    Robert Roskoski, 2020, Pharmacological Research CrossRef
  170. Nomogram Personalizes and Visualizes the Overall Survival of Patients with Triple-Negative Breast Cancer Based on the Immune Genome
    Peipei Wang et al, 2020, BioMed Research International CrossRef
  171. Receptor Tyrosine Kinase Signaling and Targeting in Glioblastoma Multiforme
    Manali Tilak et al, 2021, International Journal of Molecular Sciences CrossRef
  172. MicroRNA-214 targets PTK6 to inhibit tumorigenic potential and increase drug sensitivity of prostate cancer cells
    Patrice Cagle et al, 2019, Scientific Reports CrossRef
  173. Menstrual and Reproductive Factors, Exogenous Hormone Use, and Gastric Cancer Risk in a Cohort of Women From the European Prospective Investigation Into Cancer and Nutrition
    Eric J. Duell et al, 2010, American Journal of Epidemiology CrossRef
  174. Targeting the FGFR signaling pathway in cholangiocarcinoma: promise or delusion?
    Jing Wang et al, 2020, Therapeutic Advances in Medical Oncology CrossRef
  175. The evolving genomic landscape of urothelial carcinoma
    Alexander P. Glaser et al, 2017, Nature Reviews Urology CrossRef
  176. SNCA , a novel biomarker for Group 4 medulloblastomas, can inhibit tumor invasion and induce apoptosis
    Yong‐Xiao Li et al, 2018, Cancer Science CrossRef
  177. Dissecting the Role of the FGF19-FGFR4 Signaling Pathway in Cancer Development and Progression
    Yanan Liu et al, 2020, Frontiers in Cell and Developmental Biology CrossRef